{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-228639","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.205215+00:00","generated_at":"2026-06-11T00:06:16.638537+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acrivon announces dual WEE1/PKMYT1 inhibitor ACR-2316; plans IND by Q4 2024","bullets":["ACR-2316 is a novel dual WEE1/PKMYT1 inhibitor designed using Acrivon’s AP3 precision proteomics platform.","Preclinical studies show single-digit nM IC50 potency and potent single-agent anti-tumor activity in vitro and in vivo.","IND-enabling studies underway; IND submission targeted for Q4 2024 to initiate monotherapy development.","Updated corporate presentation confirms cash and marketable securities as of June 30, 2023, with cash runway into 2025.","Company prioritizes ACR-2316 based on preclinical profile for OncoSignature-based patient selection."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-228639","json":"https://secwatch.observer/filing/0001193125-23-228639.json","markdown":"https://secwatch.observer/filing/0001193125-23-228639.md","text":"https://secwatch.observer/filing/0001193125-23-228639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523228639/0001193125-23-228639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523228639/d479176d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:06:16.638537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}